Genelux Corporation

Genelux Corporation is a United States biotechnology company focused on developing cancer immunotherapies based on engineered oncolytic viruses. The company’s lead candidate is Olvi-Vec, also known as olvimulogene nanivacirepvec and formerly designated GL-ONC1. Olvi-Vec is a modified strain of vaccinia virus, a large, stable DNA virus that can be engineered to replicate preferentially in tumor tissue. The intended therapeutic effect combines direct destruction of cancer cells with stimulation of an immune response against the tumor. Genelux’s research and development activities are organized around its proprietary CHOICE platform. The platform is intended to support the isolation, screening, engineering, and selection of oncolytic vaccinia virus candidates. According to the company’s published descriptions, this work has produced a library of viral immunotherapy candidates, with Olvi-Vec representing the most advanced program. The company’s approach is based on the possibility that viral replication inside tumors can cause immunogenic cell death, release tumor antigens, alter the tumor microenvironment, and help recruit or activate immune cells. The principal clinical focus for Olvi-Vec has been ovarian cancer, particularly platinum-resistant or platinum-refractory ovarian cancer, a setting in which treatment options are limited and resistance to platinum chemotherapy is a major clinical problem. Genelux has reported that Olvi-Vec is administered before chemotherapy in an approach intended to prime the tumor microenvironment and potentially restore sensitivity to subsequent treatment. The company has stated that more than 150 patients have received Olvi-Vec in clinical studies. Reported studies have generally described the treatment as tolerable while providing evidence of antitumor activity, although the candidate remains investigational and is not established as an approved standard therapy. The company’s VIRO-15 Phase 2 study evaluated Olvi-Vec followed by immunochemotherapy in heavily pretreated patients with platinum-resistant or platinum-refractory ovarian cancer. The reported results included tumor responses, disease control, progression-free survival, and overall survival outcomes, with no reported grade 4 treatment-related adverse events, treatment-related discontinuations, or treatment-related deaths in the cited topline account. These findings formed part of the rationale for a subsequent Phase 3 program in platinum-resistant or platinum-refractory ovarian cancer. Clinical-trial results should be interpreted as investigational evidence rather than proof of regulatory approval or clinical benefit for all patients. Genelux has also pursued combination immunotherapy through V2ACT Immunotherapy, a modality combining Olvi-Vec with TVAX Immunotherapy, an adoptive T-cell approach developed by TVAX Biomedical. The proposed mechanism is that vaccination and viral treatment may increase tumor inflammation and improve the environment for transferred, neoantigen-specific T cells. The combination is being developed through V2ACT Therapeutics, a joint venture between Genelux and TVAX Biomedical, and is intended as a potential platform for multiple tumor types rather than a single disease indication. Genelux is headquartered in Westlake Village, California, and has additional facilities in San Diego. Its identity is that of a research-driven, late-clinical-stage oncology developer rather than a consumer-facing pharmaceutical brand. Its principal value proposition is the use of engineered vaccinia viruses to combine tumor-selective viral killing with immune activation, supported by a proprietary discovery platform and clinical development programs in solid tumors.

Genelux Corporation developed as an oncology biotechnology company centered on oncolytic viral immunotherapy. Its research model uses vaccinia virus, a non-human-pathogenic virus with a relatively large genome that can accommodate genetic engineering. The company’s objective is to identify viral constructs capable of preferentially infecting and replicating in malignant tissue while limiting undesirable effects in normal tissue. The company’s discovery work is organized around the CHOICE platform. Rather than treating a single viral construct as its entire technology base, Genelux describes CHOICE as a system for isolating, engineering, and evaluating a broad library of oncolytic vaccinia virus candidates. This platform approach is intended to support the selection of candidates with different combinations of tumor selectivity, safety characteristics, replication behavior, and immunological activity. Olvi-Vec became the company’s leading clinical candidate. The compound was formerly known as GL-ONC1 and is described as a clinical-grade formulation related to the laboratory strain GLV-1h68. Its proposed mechanism has two connected components: replication of the virus can directly damage or destroy tumor cells, while the resulting immunogenic cell death and inflammatory signaling may help expose tumor antigens and activate systemic antitumor immunity. This mechanism is particularly relevant to tumors whose local microenvironment suppresses immune-cell activity. Genelux’s most prominent clinical work has focused on ovarian cancer, especially disease that is resistant or refractory to platinum-based chemotherapy. Patients in this setting have limited treatment options, and the company has investigated a treatment sequence in which Olvi-Vec is administered before chemotherapy. The stated rationale is that viral treatment may alter the tumor microenvironment and potentially improve the response to subsequent chemotherapy. Olvi-Vec has been administered to more than 150 patients across clinical studies cited by the company. The VIRO-15 Phase 2 study evaluated Olvi-Vec-primed immunochemotherapy in heavily pretreated patients with platinum-resistant or platinum-refractory ovarian cancer. The reported findings included objective responses under RECIST 1.1, high disease-control rates, reductions in the ovarian-cancer biomarker CA-125, and reported progression-free and overall survival measures. The cited safety summary identified fever and abdominal pain among the more frequent treatment-related adverse events and reported no grade 4 treatment-related events, treatment-related discontinuations, or treatment-related deaths. These results supported further clinical development but did not by themselves establish regulatory approval. Following the Phase 2 work, Genelux moved into a Phase 3 study in platinum-resistant or platinum-refractory ovarian cancer. The development program remained investigational, with the company seeking to determine whether the approach could produce clinically meaningful benefits in a larger, more definitive trial population. Genelux also broadened its strategy through V2ACT Immunotherapy. This program combines Olvi-Vec with TVAX Immunotherapy, an adoptive T-cell treatment from TVAX Biomedical. The scientific premise is that vaccination and viral inflammation could increase the number and activity of neoantigen-specific T cells and make tumor tissue more receptive to transferred effector cells. In June 2023, Genelux and TVAX announced a United States patent covering the combination of adoptive T-cell therapy and oncolytic viral treatment. The technology was exclusively licensed to V2ACT Therapeutics, a joint venture formed by the two companies. The company is headquartered in Westlake Village, California, with additional facilities in San Diego. Its current business remains focused on research, clinical development, intellectual property, and potential partnering or commercialization of oncology therapeutics. The available reference material does not establish an approved product, commercial sales history, founding year, founder, or a complete roster of current and former executives.

• 2023

  Patent issued for the V2ACT combination

  [1]Genelux Corporationen.wikipedia.org

  A United States patent covering an adoptive T-cell and oncolytic-virus combination is issued and licensed exclusively to V2ACT Therapeutics.

• Olvi-Vec becomes the lead clinical candidate

  [1]Genelux Corporationen.wikipedia.org

  The company advances Olvi-Vec, formerly designated GL-ONC1 and derived from an engineered vaccinia virus, as its principal oncology development program.

• VIRO-15 Phase 2 study reports clinical activity

  [1]Genelux Corporationen.wikipedia.org

  Genelux reports results from a study of Olvi-Vec followed by immunochemotherapy in heavily pretreated platinum-resistant or platinum-refractory ovarian cancer.

• Olvi-Vec enters Phase 3 development

  [1]Genelux Corporationen.wikipedia.org

  The company advances Olvi-Vec into a Phase 3 program for platinum-resistant or platinum-refractory ovarian cancer.

A clinical-stage oncology biotechnology company positioned around engineered oncolytic vaccinia viruses that seek to combine direct tumor lysis with immune-system activation.

• Oncolytic viral immunotherapy

  Olvi-Vec

  Olvi-Vec, or olvimulogene nanivacirepvec, is Genelux’s lead investigational oncology candidate. Formerly known as GL-ONC1, it is a modified vaccinia virus designed to replicate preferentially in tumor tissue and produce both direct oncolysis and immune activation. The candidate has been studied in multiple clinical settings and has received particular development attention in platinum-resistant or platinum-refractory ovarian cancer, including the VIRO-15 Phase 2 study and a subsequent Phase 3 program.

• Drug-discovery platform

  CHOICE platform

  CHOICE is Genelux’s proprietary discovery and development platform for isolating, engineering, and evaluating oncolytic vaccinia virus candidates. The platform supports a library-based approach in which viral constructs can be selected and modified for characteristics such as tumor selectivity, safety, replication, and immunological activity. Olvi-Vec is the most advanced candidate described as having emerged from this platform.

• Combination immunotherapy

  V2ACT Immunotherapy

  V2ACT combines Olvi-Vec with TVAX Immunotherapy, an adoptive T-cell approach developed by TVAX Biomedical. Its proposed mechanism pairs virus-induced tumor inflammation with the transfer of neoantigen-specific effector T cells. The program is associated with V2ACT Therapeutics, a joint venture between Genelux and TVAX Biomedical, and is intended as a potential combination modality across multiple cancer types.

• 2023

  Create and license the V2ACT combination platformM&A

  Background

  Genelux and TVAX Biomedical pursued a combination of oncolytic viral therapy with adoptive, neoantigen-specific T-cell therapy.

  Action taken

  The companies formed V2ACT Therapeutics and exclusively licensed intellectual property covering the combination approach after issuance of a United States patent.

  Aftermath

  The arrangement expanded Genelux’s development strategy beyond Olvi-Vec monotherapy or chemotherapy combinations, although the cited material does not describe a commercial product launch.

  Source

• Advance Olvi-Vec from Phase 2 toward Phase 3Generation change

  Background

  Results reported from the VIRO-15 Phase 2 study provided the stated clinical rationale for testing Olvi-Vec in a later-stage study of platinum-resistant or platinum-refractory ovarian cancer.

  Action taken

  Genelux entered a Phase 3 clinical program for the lead candidate.

  Aftermath

  The program remained investigational; the reference material does not report regulatory approval or a commercial launch.

  Source

• 2021.11.18

  Reported2021.11.18

  Genelux grants ELIAS Animal Health worldwide exclusive license for V-VET1[2]Genelux 授予 ELIAS Animal Health V-VET1 全球独家许可prnewswire.com

  Genelux announced an exclusive worldwide licensing agreement with ELIAS Animal Health for V-VET1, granting ELIAS rights to develop and commercialize the veterinary cancer treatment candidate.

Read more

1. 1Genelux Corporationen.wikipedia.org
2. 2Genelux 授予 ELIAS Animal Health V-VET1 全球独家许可prnewswire.com